

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zylox-Tonbridge Medical Technology Co., Ltd.

歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

VOLUNTARY ANNOUNCEMENT NATIONAL MEDICAL PRODUCTS ADMINISTRATION GRANTED MARKETING APPROVAL FOR TONBRIDGE TWIN SNAKE™ RADIAL ACCESS DISTAL SUPPORT CATHETER

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**”, together with its subsidiary, the “**Group**”, “**we**” or “**our**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development of the Group.

The Company is pleased to announce that the Tonbridge Twin Snake™ Radial Access Distal Support Catheter, independently developed in-house by us, has been recently granted the marketing approval by the National Medical Products Administration (the “**NMPA**”) of the People’s Republic of China (the “**PRC**”). The marketing of the product is ahead of the expected approval in 2024 as disclosed in the Company’s interim report for 2023. As of the date of this announcement, the Company has obtained approvals from the NMPA for a total of 31 products in the PRC.

The Tonbridge Twin Snake™ Radial Access Distal Support Catheter consists of an ultra-selective catheter and a therapeutic catheter that coordinate with each other, enabling non-invasive relative motion between the catheters and reducing irritation to the inner wall of the blood vessel. The head end of the ultra-selective catheter is designed with a variety of shapes, which is more suitable for the arch shape of Chinese people, thereby realizing ultra-selective target vessels in various scenarios; the therapeutic catheter is available in 6F and 7F models to meet various clinical needs.

The trans-radial approach has a number of advantages in terms of anatomy, safety, patient experience, and hospital costs. The trans-radial approach is more superficial than the trans-femoral approach and is not in close proximity to vulnerable key structures during the procedure. The dual blood supply of hands can minimize hazards to the patient in the event of thrombosis/entrapment of a trans-radial approach. Due to the smaller incision, the trans-radial approach can achieve hemostasis without a vascular closure device, help the patient to walk upright after the procedure, and significantly improve patient comfort. Less post-operative care is required after the procedure, with shorter time of hospitalization, which can reduce relevant hospital costs. In the PRC, the use of trans-radial approach for coronary is over 95%. The trans-radial approach for neurointerventions is relatively new, with a lack of neurointervention access devices specifically designed for the trans-radial approach. Currently, there is still a huge potential for development of trans-radial approach for neurointerventions. The marketing of the Tonbridge Twin Snake™ Radial Access Distal Support Catheter provides a new direction and is expected to create new solutions for the trans-radial approach for neurointerventions.

By order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, December 6, 2023

As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Mr. Stephen Hui Wang, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive Directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive Directors.